As the US considers starting vaccinations in children, federal health officials stated late Friday that kid-size doses of Pfizer’s Covid-19 vaccine appear extremely effective in preventing symptomatic infections in elementary school children and created no unforeseen safety issues.
The FDA published its review of Pfizer’s data ahead of a public meeting next week to discuss whether the vaccines are ready for the country’s roughly 28 million children aged 5 to 11. The agency will put the subject to a panel of outside vaccination experts for a vote.
